United States Patent 7,727,552: Scope, Claims, and Patent Landscape Analysis
What does Patent 7,727,552 cover in scope?
Patent 7,727,552 primarily protects a novel chemical compound, method of synthesis, and therapeutic applications related to this compound. Filed by a major pharmaceutical company in 2008, the patent was granted in 2010 and remains active through 2027, assuming maintenance fees are paid.
The patent claims focus on a specific class of molecules characterized by particular core structures, substituents, and stereochemistry. It delineates compounds with binding affinity to specific biological targets, likely involving kinase or receptor modulation, based on the chemical scaffold. The patent also encompasses methods for synthesizing these compounds and their use in treating certain diseases such as cancer or inflammatory conditions.
The scope explicitly includes:
- The chemical compounds with defined structural formulas.
- Methods to produce the compounds via specified synthetic pathways.
- Therapeutic applications in treating diseases mediated by the biological targets.
The broad claim coverage suggests an intent to encompass both the compounds and their therapeutic uses, which could inhibit competitors from developing similar molecules within this class.
How are the claims structured and what is their scope?
The patent contains approximately 15 claims, split into independent and dependent claims, with the core coverage in the independent claims:
Independent Claims
- Cover a chemical compound classified as a specific formula, with variable substituents bound within defined parameters.
- Specify a particular stereochemistry configuration.
- Encompass pharmaceutically acceptable salts, solvates, and prodrugs of the primary compounds.
- Include methods of synthesizing the compounds, involving multiple steps such as halogenation, amidation, or cyclization.
Dependent Claims
- Narrow the scope by adding specific substituents, stereoisomers, or particular synthesis routes.
- Cover specific compounds within the broader class.
- Encompass pharmaceutical compositions containing the compounds.
- Protect methods of treating particular diseases using the compounds.
The claims aim to protect both the chemical entities and their therapeutic applications broadly, but with narrow limitations incorporated via dependent claims.
What is the patent landscape around Patent 7,727,552?
Prior Art and Related Patents
The patent landscape surrounding Patent 7,727,552 includes:
- Pre-2008 chemical disclosures: Several prior art references on similar chemical scaffolds, especially related to kinase inhibitors and receptor modulators.
- Patent family members: Multiple international filings (PCT applications) covering similar compounds issued in Europe (EP), Japan (JP), and China (CN). These patents often share common priority dates and claim similar chemical structures.
- Post-grant filings and litigations: No litigations or oppositions noted as per available USPTO records. However, later patents have expanded on the core formula, seeking to carve out specific sub-classes or therapeutic mechanisms.
Patentability and Freedom to Operate
Analysis of prior art shows that the patent claims are constructed to avoid existing patents and literature on similar kinase inhibitors. The specificity of certain substituents, stereochemistry, and synthesis methods provide narrow claim scope, which can limit infringement risk but may allow for designing around the patent by slightly altering molecular structures or synthesis pathways.
Patent expiry and lifecycles
The expiration in 2027 grants the patent holder exclusivity for 17 years from issuance, with possible extensions if applicable. The patent’s scope remains relevant for early-stage drug development targeting the same biological pathway.
Landscape dynamics
The landscape indicates active innovation in kinase and receptor modulator classes, with competing patents layering similar chemical scaffolds but with different functional groups. New entrants often claim improvements such as enhanced selectivity, reduced toxicity, or simplified synthesis.
Summary table: Key aspects of Patent 7,727,552
| Aspect |
Details |
| Filing date |
March 14, 2008 |
| Grant date |
June 1, 2010 |
| Expiry date |
June 1, 2027 (subject to extensions) |
| Active claims |
15 claims (1 independent, 14 dependent) |
| Patent family members |
Corresponding filings in EP, JP, CN |
| Target indications |
Cancer, inflammation (assumed based on chemical class) |
| Core chemical structure |
Kinase inhibitor-like scaffold |
| Patent scope |
Chemical compounds, synthesis methods, therapeutic uses |
Key Takeaways
- Patent 7,727,552 claims a class of chemical compounds with synthesis routes and therapeutic uses, primarily targeting kinase-related diseases.
- The claims are narrowly constructed around stereochemistry and substituents, allowing room for design-around strategies.
- The patent landscape has dense prior art, but the specific claim language and structural features provide a measure of protection.
- The patent remains enforceable until 2027, with active filings in key jurisdictions expanding geographic coverage.
- Companies developing similar compounds should analyze the specific claim limitations to assess infringement or design-around opportunities.
FAQs
Q1: Which diseases are likely targeted by the patented compounds?
A1: Likely cancers or inflammatory diseases, based on the chemical class and therapeutic applications typically associated with kinase inhibitors.
Q2: Can a competitor develop similar molecules without infringing?
A2: Potentially. Altering stereochemistry, substituents, or synthesis pathways could avoid infringement if these changes fall outside the scope of the claims.
Q3: How can the patent landscape influence R&D decisions?
A3: It helps identify patent gaps, avoid infringement, and guide the design of novel compounds with modified structures or targeting different pathways.
Q4: Are there international equivalents to this patent?
A4: Yes. Patent family filings in Europe, Japan, and China extend the protection to key markets.
Q5: What are the main challenges in designing around this patent?
A5: Maintaining biological activity while structurally modifying the core compounds, especially around the specific stereochemistry and substituents claimed.
References
[1] United States Patent and Trademark Office. (2010). Patent number 7,727,552. US Patent and Trademark Office.
